ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Protective effects of caffeine on aluminum-induced ovarian toxicity in a mouse model.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the protective effects of caffeine (Caf) against aluminum chloride (AlCl₃)-induced ovarian toxicity in female Swiss Albino mice. Twenty-four adult female mice were equally divided into four groups (n = 6): control, Caf (40 mg/kg, oral), AlCl₃ (50 mg/kg, i.p.), and AlCl₃ + Caf, administered for seven consecutive days. AlCl₃ administration was associated with oxidative stress, as indicated by decreased ovarian glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) levels, along with increased malondialdehyde (MDA) levels. Caf pretreatment appeared to restore antioxidant enzyme activities and attenuate lipid peroxidation. Serum caspase-3 and caspase-9 levels were elevated following AlCl₃ administration, whereas Caf pretreatment was associated with reduced caspase levels. AlCl₃ exposure also led to increased serum interleukin-6 (IL-6), nuclear factor kappa B (NF-κB), and tumor necrosis factor-alpha (TNF-α) levels. Histopathological examination revealed granulosa cell degeneration, follicular atresia, disruption of the corona radiata, and reduced follicle numbers in the AlCl₃ group, whereas Caf appeared to alleviate these lesions, as confirmed by histopathological scoring and follicle counts. Immunohistochemical analyses demonstrated reduced anti-Müllerian hormone (AMH) and AMH receptor 2 (AMHR2) expression and increased caspase-3 immunoreactivity following AlCl₃ exposure. Caf pretreatment was associated with increased AMH and AMHR2 expression and reduced caspase-3 immunoreactivity. These findings suggest that Caf may exert protective effects against AlCl₃-induced ovarian injury, potentially through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms.
Indexed as
Identifiers
42728407What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.